Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era

Autor: Fausto Rossini, Elisa Doni, Angelo Belotti, Ivana Casaroli, Enrico Maria Pogliani, Silvia Bolis, Sara Pezzatti, Pietro Pioltelli
Rok vydání: 2014
Předmět:
Oncology
Male
Cancer Research
Pathology
medicine.medical_treatment
Follicular lymphoma
Aggressive lymphoma
Monocytes
Antibodies
Monoclonal
Murine-Derived
Leukocyte Count
immune system diseases
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Lymphocytes
Lymphoma
Follicular
Aged
80 and over
Hematology
Middle Aged
Prognosis
medicine.anatomical_structure
Treatment Outcome
Vincristine
Rituximab
Female
Lymphoma
Large B-Cell
Diffuse
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Antineoplastic Agents
Young Adult
Internal medicine
medicine
Humans
Cyclophosphamide
Aged
Neoplasm Staging
Retrospective Studies
Chemotherapy
business.industry
Monocyte
medicine.disease
Survival Analysis
Lymphoma
Doxorubicin
Peripheral blood lymphocyte
Prednisone
business
Diffuse large B-cell lymphoma
Zdroj: Clinical lymphoma, myelomaleukemia. 15(4)
ISSN: 2152-2669
Popis: Diffuse large B-cell lymphoma is an aggressive lymphoma and a large number of studies have therefore focused on the search for prognostic factors. The same interest concerns FL, for which identification of patients candidates for watch and wait (WW) strategy is still an option. Studies about the number and type of lymphocytes and monocytes detectable in patients with Hodgkin and non-Hodgkin lymphomas indicate they might affect the pathogenesis and prognosis of these diseases. LMR is recently under investigation as a new prognostic parameter in DLBCL; the role of this ratio in FL in the rituximab era is unknown.We retrospectively analyzed 137 DLBCL and 132 FL patients referred to our institution; among FL pts, a WW approach was performed at diagnosis for 42 patients. The remaining patients were treated with rituximab-containing therapy. We analyzed different LMR cutoff values at diagnosis and we wanted to investigate the prognostic effect among DLBCL and FL.We found that the most discriminative LMR was 2.4 for DLBCL and 2 for FL. Among DLBCL patients, an LMR value 2.4 was associated with a worse 2-year progression-free survival (PFS), and we observed no difference in overall survival and complete response rate. Considering FL patients, LMR2 was associated with a longer time to treatment start compared with the LMR 2 group (P = .0096). Among the 92 patients treated with rituximab chemotherapy, 2-year PFS was superior in the LMR2 group.LMR at diagnosis is a simple tool to better define long-term outcome of DLBCL and FL patients. The use of this tool might better define selection in FL of ideal candidates for WW strategy.
Databáze: OpenAIRE
Externí odkaz: